PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols

SIMPLE SUMMARY: The introduction of therapies with immune checkpoint inhibitors targeting the programmed cell death protein 1 and its ligand (PD-L1) axis in head and neck squamous cell carcinoma prompted the need of reliable bio-selectors to stratify patients that would benefit from these treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Crosta, Simona, Boldorini, Renzo, Bono, Francesca, Brambilla, Virginia, Dainese, Emanuele, Fusco, Nicola, Gianatti, Andrea, L’Imperio, Vincenzo, Morbini, Patrizia, Pagni, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830149/
https://www.ncbi.nlm.nih.gov/pubmed/33466794
http://dx.doi.org/10.3390/cancers13020292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830149/
https://www.ncbi.nlm.nih.gov/pubmed/33466794
http://dx.doi.org/10.3390/cancers13020292

Ejemplares similares